|
|
609 Broadway NE #215
Albuquerque, NM 87102 United States
phone:(505) 821-0875
fax:
|
|
| Symbol |
BMOD |
| Exchange |
OTC |
| Founded |
1990 |
| Employees |
9 |
|
|
| www.biomoda.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Focused on the development and commercialization of cost-effective, non-invasive, accurate and reproducible diagnostic tests for the early detection of cancer. |
|
| Management |
| John J. Cousins, President, Chief Executive Officer; Constance Dorian, Vice President of Technical Operations; Tim Zannes, General Counsel; |
| |
|
|
|
|
|
|
|
| Keywords |
| cancer, diagnostics, molecular markers |
|
|
|
| Description |
|
Biomoda is a cancer diagnostics company focused on the development of an inexpensive, simple, highly accurate in-vitro test for the early detection of lung cancer. The CyPath� assay is based upon Biomoda�s patent estate centered on molecular marker technology originally developed at the Los Alamos National Laboratory. The Biomoda technology directly addresses a global health crisis by making the early diagnosis of the deadliest cancers available at an affordable cost to large populations worldwide. |
|
| Products / Services |
The CyPath diagnostic is currently in clinical trials and can be used only for investigational purposes. Results of the current study and additional clinical trials will be submitted to the U.S. Food and Drug Administration (FDA) as required prior to approval for commercial use. If approved by the FDA, Biomoda�s simple, non-invasive in-vitro test for early detection of lung cancer is expected to provide compelling value to the healthcare system through cost savings and improved patient outcomes.
|
|
| Technology / Differentiation |
The CyPath assay is based upon Biomoda�s patent estate centered on molecular marker technology originally developed at Los Alamos National Labs. TCPP (5,10,15, 20-Tetrakis (Carboxyphenyl) Porphine), a synthetically manufactured porphyrin, is the active ingredient and the basis of CyPath.
CyPath binds to cancerous and pre-cancerous cells in tissue samples and causes them to fluoresce red under ultraviolet light. In internal validation testing, the CyPath� assay showed near 100% accuracy and 100% specificity with no false positives or false negatives. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members